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 EXPLORING A THERAPEUTIC ROLE FOR IGF1R INHIBITORS IN TRIPLE-
NEGATIVE BREAST CANCER  
Onyinye Offor, Catherine Sullivan, Sofya Rodov, Kimberly Lezon-Geyda, Lyndsay 
Harris.  Section of Medical Oncology, Department of Internal Medicine, Yale University, 
School of Medicine, New Haven, CT 
SUMMARY 
There is substantial preclinical and clinical data suggesting that triple-negative 
breast cancer (TNBC), a breast cancer subtype that lacks HER-2, estrogen- and 
progesterone-receptor expression is associated with obesity, insulin resistance and 
metabolic derangements involving the insulin-like growth factor (IGF) pathway.  We 
hypothesized that IGF-1 receptor (IGF1R) targeted therapy will be active in TNBC and 
will enhance the activity of chemotherapeutic agents used for breast cancer.  We aimed 
(1) to determine if AG1024, an experimental tyrosine kinase inhibitor of IGF-1R, or 
Figitumumab, a human anti-IGF1R antibody, has a cytotoxic effect on TNBC cell lines as 
a single agent and (2) to determine if combining AG1024 or Figitumumab with 
conventional chemotherapeutic agents, doxorubicin or paclitaxel, in TNBC cell lines 
would enhance their cytotoxic effects.  To evaluate the effect of these agents, 
cytotoxicity assays were conducted using four TNBC cell lines (MDA-MB-231, MDA-MB-
468, SUM149 and BT20) and a non-TNBC cell line, MCF7, for comparison. 
Our results showed that AG1024 caused a dose-dependent decrease in cell 
viability in TNBC cell lines and that TNBC cell lines were more sensitive to AG1024 than 
non-TNBC cell lines.  Also, the cytotoxic effects of AG1024 were enhanced in all TNBC 
cell lines by the addition of paclitaxel and in three out of four TNBC cell lines upon 
adding doxorubicin.  Figitumumab monotherapy failed to have cytotoxic effects on TNBC 
cell lines but the anti-IGF1R antibody cytotoxic effects were enhanced by addition of 
doxorubicin in two TNBC cell lines and by addition of paclitaxel in one TNBC cell line.  
This study suggests that therapies targeting the IGF1R may have clinical application in 
the treatment of TNBC and tyrosine kinase inhibitors, such as AG1024, may be better 
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1.  INTRODUCTION 
 
 Microarray profiling studies have led to the identification of distinct breast 
cancer subtypes1.  Breast malignancies are designated “triple-negative” when 
immunohistochemical and fluorescence in situ hybridization testing reveals a lack 
of HER2/neu expression, estrogen- and progesterone-receptor expression1. This 
subtype of breast cancer frequently resembles the outer or basal layer of the 
breast duct rather than the inner layer or lumen of the breast duct.  However, the 
triple-negative subtype is not synonymous with basal-like breast cancer. Basal-
like malignancies express one or more the basal cytokeratins (CK 5/6, CK14, 
CK17 and CK903), laminin and fatty acid binding protein1.  They also tend to be 
estrogen- and progesterone-receptor negative.  55-85% of basal-like 
malignancies lack estrogen- and progesterone-receptor expression.  Depending 
on the study, between 65-90% of triple-negative tumors are basal-like.  Clearly, 
there are basal-like malignancies that are not triple-negative and vice-versa.
 Triple-negative breast cancer (TNBC) accounts for 10-17% of all breast 
cancer cases and is more prevalent in pre-menopausal African-American and 
Hispanic women, compared to Caucasian and post-menopausal African-
American women2.  Moreover, it carries a worse prognosis than its counterparts.  
Up to 50% of patients will relapse and die of their disease even when it is 
detected during its early stages3, 4. Furthermore, they cannot be treated with 
therapies such as tamoxifen or trastuzumab (Herceptin) that have significantly 
improved outcomes in estrogen receptor-positive or HER-2 positive breast  
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cancer patients, respectively.   Therefore, it is imperative to identify novel 
therapies for this patient population. 
Although the exact pathogenesis of TNBC is not clear, TNBC is more 
common in women with an elevated waist-hip ratio5 and increased body mass 
index (BMI)6. Obesity, defined as a body mass index (BMI) 30kg/m2, is an 
established risk factor for breast cancer in post-menopausal women and 
prognostic factor in both pre- and post-menopausal women7, 8. Obesity causes 
changes in steroid metabolism that directly or indirectly contribute to breast 
carcinogenesis; one of these consequences is the up-regulation of insulin and 
insulin-like growth factors (IGFs)9, 10. This suggests that abnormalities in 
metabolism may be implicated in the development of TNBC. 
Insulin receptors (IRs) were first detected on mammary carcinoma 
samples and shown to bind insulin in 197711. Insulin receptors and insulin-like 
growth factor receptors (IGFRs) are both tetrameric tyrosine kinases found on 
the cell surface.  These tetramers are comprised of two half-receptors consisting 
of an extracellular -chain that mediates ligand binding and an intracellular -
chain that contains the tyrosine kinase domain.  The gene encoding the insulin 
receptor can be differentially spliced to yield the fetal splice variant, IRA, or the 
classic adult isoform, IRB12-14.  IRA is thought to be involved in growth and 
proliferation whereas IRB is associated with carbohydrate metabolism15. 
In vitro studies have shown that insulin, at physiologic concentrations, stimulates 
DNA synthesis and thus cell proliferation in breast cancer cells16, 17.  In patients  
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with hyperinsulinemia, prospective studies have shown that women with insulin 
levels in the highest quartile have twice the risk of recurrence and triple the 
mortality risk from all breast cancer subtypes, compared to women with normal 
insulin levels18.  Type II diabetics with breast cancer are known to have more 
rapid disease progression and approximately 40% increase in 5-year mortality  
due to their breast cancer19.  Of note, 1,1-dimethylbiguanide hydrochloride 
(Metformin), an anti-diabetic drug that stabilizes glucose flux and reduces 
insulin resistance via activation of the AMP-kinase dependent pathway, lowers 
insulin levels by 22% in early stage breast cancer patients20 and improves 
survival in diabetic cancer patients21.  Also, higher pathologic complete response 
rates are observed in diabetics who take Metformin compared to those who do 
not (24% versus 8%)22. Finally, Metformin inhibits cellular proliferation and 
induces apoptosis in TNBC in vitro and in vivo23.  These effects have not been 
demonstrated in non-TNBC cell lines. 
Given the common ancestry and similarities in the signaling pathways 
downstream of the insulin and insulin-like growth factor 1 receptor (IGF1R), the 
associations between elements of the IGF axis and carcinoma have also become 
of interest to the scientific community.  The insulin-like growth factor (IGF) 
ligands I and II play important roles in the regulation of cellular proliferation, 
differentiation and survival.  They are primarily synthesized in the liver and both 
bind to IGF1R to exert their effects via the RAS-MAPK and PI3K pathways.  
IGF2R, on the other hand, does not appear to transmit proliferation and survival  
 
 4
signals; rather, it seems to sequester the ligands and thereby act as a negative 
regulator of the pathway.  Of note, IRs and IGF1R can form hybrid receptors; 
malignant neoplasms have been shown to preferentially express IRA-IGF1R 
hybrid receptors 24, 25.   Several landmark studies have also shown that IGF1R is 
implicated in mitogenesis, malignant transformation, invasion and resistance to  
some anticancer therapies particularly those that target the ER and the epidermal 
growth factor receptor (EGFR) members, EGFR26 and HER227. 
By 1984, in vitro studies had shown IGF I and II have mitogenic activity in 
breast carcinoma cell lines28.  In 1987, IGF1R was detected in primary human 
breast carcinoma specimens29.  As early as 1989, blockade of the IGF1R using 
-IR-3, a monoclonal antibody, was proven to inhibit growth in vitro and thwart 
the mitogenic effect of IGF-I in breast cancer cell lines.  Of note, -IR-3 inhibited 
the growth of TNBC in nude mice but failed to act similarly in estrogen-receptor 
positive breast cancer cells30.  
Several studies have also attempted to correlate expression of IGF 
components with prognosis in breast cancer patients.  Initially, high IGF1R 
expression was believed to be a favorable prognostic factor31.  In a series of 184 
breast cancer specimens, the average IGF1R content was nearly ten times 
higher in breast carcinomas than in normal breast tissue and IGF1R levels were 
significantly higher in the low-risk group (ER+/PR+) than in high-risk individuals 
(ER-/PR-).  However, a recent study by Law et al32 suggests that detection of 
phosphorylated IGF1R (p-IGF1R), not total IGF1R, better predicts survival and is  
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associated with poor prognosis. They evaluated 438 cases of invasive breast 
cancer using  p-IGF1R antibody on tumor tissue microarrays.  Their data suggest  
that p-IGF1R rather than total IGF1R was indicative of survival and that p-IGF1R 
was detected in all subtypes of breast cancer represented in their cohort (triple-
negative 41.9%, luminal 48.1%, HER2 64.3%).  An IGF-I molecular signature 
associated with poor disease outcome and negative prognostic factors has also 
been postulated.  Through in vitro stimulation of breast cancer cells with IGF-I, 
Creighton et al defined an expression pattern of over 800 genes that were either 
up- or down-regulated.  Analysis of gene expression in clinical breast tumors 
revealed that ER-negative tumors displayed high expression of genes induced by 
IGF-I and low expression of genes repressed by IGF-I33.    
Despite evidence suggesting a role for IGFs and IGF1R in breast 
carcinoma, it was not until the beginning of the 21st century that the 
pharmaceutical industry began to manufacture therapies targeted to IGF1R34.  
There are two main classes of anti-IGF1R therapies:  receptor-specific antibodies 
and receptor kinase inhibitors.  IGF1R-specific antibodies include CP-751871 
(Figitumumab:  Pfizer), AMG479 (Amgen), h10h5 (Genentech), AVE1642 
(Sanofi-Aventis), A12 (Imclone), MK0646 (Merck) and R1507 (Roche) and BMS-
536924 (Bristol Myers Squibb).  AG538 and AG1024 (3-bromo-5-t-butyl-4-
hydroxy-benzylidenemalonitrile) are two of the IGF1R tyrphostins, receptor 
tyrosine kinase inhibitors, which have been developed.  AG1024 is only used 
experimentally and has not been tested in humans.   
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AG1024 binds to the active site of both IGF1R and IR to induce conformational 
changes that prevent substrates such as IRS-1 and ATP from binding to the 
receptors.   It has a lower affinity for IR and a lower IC50 for IGF1R (7M for 
IGF1R compared to 57M for IR35).  Early studies of AG1024 in hormone 
receptor-positive and TNBC cell lines have shown that as a single agent, it is 
effective at reducing proliferation and inducing apoptosis36-38. Using hormone 
receptor-positive MCF7 cells, Chakraborty et al showed that combining -IR3, a 
murine anti-IGF1R monoclonal antibody or AG1024, an IGF1R tyrosine kinase 
inhibitor, with anti-estrogen reagents leads to greater growth inhibition than using 
these reagents alone39.   Other studies have corroborated these findings40. 
Initial studies of Figitumumab in breast cancer were conducted using 
MCF7, an estrogen- and progesterone-receptor positive breast carcinoma cell 
line41. Figitumumab binds to the extracellular domain of IGF1R homodimers and 
heterodimers; it does not cross-react with IR.  Furthermore, consecutive 
immunoblots showed that culturing MCF7 cells with 1g/mL of Figitumumab 
caused a time-dependent decrease in IGF1R with maximal effect attained 
between 3 and 4 hours of exposure.  Confocal microscopy also revealed that the 
same concentration of Figitumumab induced internalization of IGF1R receptors 
within 15 minutes of exposure.  In tumor xenograft models using MCF7 cells, 
Figitumumab alone inhibited tumor growth and when combined with tamoxifen, 
an anti-estrogen therapy for estrogen-receptor positive patients, inhibited tumor 
growth more than Figitumumab or tamoxifen alone41.  A similar effect was  
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produced when Figitumumab and doxorubicin (Adria) were combined in 
3T3/IGF1R-transfected tumors41. 
In recent clinical trials involving patients with multiple myeloma, lung 
cancer or other solid tumors, several agents have induced responses when 
acting as single-agents and the IGF1R antibodies generally have a favorable  
toxicity profile42, 43.  These antibodies cause increases in the serum concentration 
of human growth hormone and IGF-I but there is no evidence to suggest that 
increases in IGF-I can overcome the suppression caused by IGF1R inhibitors42.  
To date, clinical trials of IGF1R targeted therapies in breast cancer include a 
Phase I trial of neoadjuvant Figitumumab in early stage, operable breast cancer 
(ClinicalTrials.gov identifier: NCT006352) and a Phase I trial of Figitumumab and 
Pegvisomant, a growth hormone antagonist, in advanced solid tumors 
(ClinicalTrials.gov identifier: NCT00976508). 
Although there is evidence that antagonizing IGF1R in TNBC may be of 
clinical benefit, most of the studies involving the newly developed IGF1R 
antibodies have focused on hormone receptor-positive breast cancer models and 
there are few preliminary studies of IGF1R antibodies in TNBC or TNBC cell 
lines.  A recent study by Zha et al40 examined the effect of h10H5, an anti-human 
IGF1R monoclonal antibody, in several hormone receptor-positive and TNBC cell 
lines.  The cell lines that showed sensitivity to h10H5 were primarily ER-positive 
with intermediate to high levels of IGF1R expression.  MCF7, a hormone 
receptor-positive breast carcinoma cell line, was shown to respond to h10H5  
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whereas MDA-MB-231 and MDA-MB-468, two TNBC negative cell lines failed to 
show sensitivity to this agent.  Nonetheless, the proliferation of three ER-negative  
cell lines (HCC1143, HDQP1 and SW527) with low to intermediate IGF1R 
expression was inhibited by h10H5.   
Our study proposes to evaluate the activity of IGF1R receptor antibodies 
and the tyrophostin, AG1024, in TNBC cell lines to explore the therapeutic 
potential of these agents in this breast cancer subtype. In this study, we will 
investigate TNBC cell lines that were not represented in previously published 
studies. Finally, we will explore the potential for IGF1R targeted therapies to 
enhance the cytotoxicity of conventional chemotherapeutic agents that are the 
mainstay of treatment for TNBC patients. In this study, we combine doxorubicin, 
an anthracycline that interferes with DNA synthesis, and paclitaxel, a taxane that 
stabilizes microtubules, with Figitumumab and AG1024 to determine if greater 
cellular inhibition is achieved using these conventional chemotherapeutic agents 










2.  PURPOSE AND HYPOTHESIS  
There is substantial preclinical and clinical data suggesting that TNBC is 
associated with obesity, insulin resistance and metabolic derangements 
(involving IGF and IGF1R).  We hypothesize that IGF1R targeted therapy will be 
active in TNBC cell lines and will enhance the activity of chemotherapeutic 
agents used for breast cancer.  
 
3. SPECIFIC AIMS 
Specific Aim #1:  To confirm that AG1024, an experimental tyrosine kinase 
inhibitor of IGF-1R, has an anti-proliferative effect on TNBC cell lines as a single 
agent. 
 
Specific Aim #2:  To determine if Figitumumab, a human anti-IGF1R antibody 
targeting the extracellular domain of the receptor, has an anti-proliferative effect 
on TNBC cell lines as a single agent. 
 
Specific Aim #3:  To determine if AG1024 has an additive cytotoxic effect when 
combined with conventional chemotherapeutic agents, doxorubicin or paclitaxel, 
in TNBC cell lines. 
 
Specific Aim #4: To determine if Figitumumab has an additive cytotoxic effect 
when combined with conventional chemotherapeutic agents, doxorubicin or 
paclitaxel, in TNBC cell lines. 
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Specific Aim #5:  To compare the effects of AG1024 and Figitumumab on TNBC 
cell lines with their effects on an ER- and PR-positive breast cancer cell line, 
MCF7 (alone or in combination with chemotherapeutic agents). 
 
Specific Aim #6:  To compare the relative levels of IGF1R expression in the 
TNBC and hormone-receptor positive cell lines utilized in this study and 


















4. MATERIALS AND METHODS 
 
Cell Culture 
TNBC cell lines (MDA-MB-231, MDA-MB-468, BT-20) were maintained in RPMI 
1640 supplemented with 10% fetal bovine serum (FBS), L-glutamine, sodium 
pyruvate and gentamicin.   SUM-149 was maintained in F-12 media containing 
5g/mL insulin, 1g/mL hydrocortisone, 10mM or 1% HEPES, 5% FBS and 
gentamicin.  The MCF-7 cell line was maintained in Dulbecco’s Modified Eagles 
Medium (DMEM) supplemented with 10% fetal bovine serum, L-glutamine, 
sodium pyruvate, 7g/mL insulin and gentamicin.  All reagents were purchased 
from Invitrogen except HEPES and hydrocortisone which were purchased from 
Sigma.  All cell lines were cultured in a 37C humidified atmosphere containing 
95% air and 5% CO2. 
 
Reagents 
AG1024, an IGF1R tyrosine kinase inhibitor (Calbiochem:  San Diego, CA), was 
dissolved in 164L of DMSO to prepare a 20mM stock solution.  This solution 
was stored at -20C.  CP-751871 (Figitumumab) was given as part of 
collaboration with Dr. Michael DiGiovanna (Yale Cancer Center) and was 
received as a stock solution of 6.1mg/mL stored at 4C.  Paclitaxel (Taxol:  
Bristol Myers Squibb, Princeton, NJ) and doxorubicin (Adria:  Adria Laboratories 
Incorporated, Columbus, OH) were stored at concentrations of 7mM and 
2mg/mLrespectively. Paclitaxel was stored at room temperature and doxorubicin  
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was stored at 4C.  All of the stock solutions were diluted in OptiMEM (Invitrogen) 
prior to their addition to the cells. 
 
Western Blotting 
All cell lines were trypsinized, centrifuged and washed in PBS with EDTA-free 
protease inhibitor cocktail (Roche: Indianapolis, IN).  Cells were centrifuged, PBS 
was aspirated and the cell pellet was stored at -80C.  After thawing the frozen 
pellet, the cells were resuspended in 100-120L of CelLytic M lysis reagent 
(Sigma-Aldrich, St Louis, MO) containing protease inhibitor cocktail (Roche).  
This mixture was sonicated on ice for 10 seconds then incubated for 15 minutes 
at 4C followed by centrifugation at maximum speed for 15 minutes at 4C.  A 
standard curve was calibrated using BSA (2g/L).  Nine microliters of distilled 
water and 200L of BioRad protein assay dye were added to 1L of each sample 
to calculate each sample protein concentration. 10L of lysis buffer and Laemmli 
sample buffer was added to 30g of protein from each cell line.  These mixtures 
were boiled for 5 minutes then cooled on ice for 5 minutes and proteins were 
separated on Bio-Rad Ready 4-20% Tris-HCl gels. Proteins were separated on 
an SDS-PAGE 4-20% Tris-HCl gel (Bio-Rad: Hercules, CA). Proteins were then 
transferred onto a nitrocellulose membrane (Bio-Rad) in a transfer buffer 
containing 20% methanol. Western blot analysis was performed with anti-IGF1R 
antibody (Cell Signaling Technology: Danvers, MA) and appropriate secondary 
antibodies.  Images were taken on a ChemiDoc XL (Bio-Rad). 
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Cell Proliferation Assays 
To determine the optimal concentration of cells per well for 5-day drug assays, a 
proliferation assay was performed for each cell line.  All cell lines were harvested, 
resuspended in OptiMEM and plated in triplicate in 96-well plates at four or more 
different concentrations of cells per well.  Cells were allowed to adhere for 24 
hours then 10L of Cell Proliferation Reagent, WST-1 (Roche Diagnostics:  
Mannheim, Germany), was added to each well.  Plates were incubated for 2 
hours when optical density at 450nm was determined using a microplate reader 
(EL-800 Universal microplate reader:  Bio-Tek instruments, Vinooski, VT).  The 
WST-1 colometric assay was performed daily and a proliferation curve was 
produced using the readings from Days 0-5.  The optimal cell concentration at 
Day 0 was defined as the concentration at which cells remain in the log phase of 
growth on Day 5. One thousand cells/well was estimated as the optimal 
concentration for MCF7 and BT-20 cells.  Fifteen hundred cells/well was 
estimated to be the optimal concentration for MDA-MB-231 cell line.  Three 
thousand cells/well was estimated to be the optimal concentration for MDA-MB-
468 and SUM149 cells.  
 
Cytotoxicity Assays 
A.  All cells were harvested, resuspended in OptiMEM and plated in triplicate in 




37C, drugs were added to the cells.  Cells were not confluent at the time drug 
was added.  Five concentrations of each drug were tested in triplicate.  Paclitaxel 
was used at 0.2nM, 2nM, 20nM, 200nM and  
2000nM.  AG1024 and doxorubicin were tested at 0.01M, 0.1M, 1M, 10M 
and 100M.  Figitumumab was tested at 0.1M, 1M, 10M, 100M and 
1000M.  The WST-1 colormetric assay was performed on Day 5.  The optical 
densities of the controls (the cells not exposed to the drugs) were averaged to 
obtain the mean.  This number represented 100% survival of cells.  The percent 
of surviving cells in each well containing drug was calculated using the following 
equation:  (optical density in drug-treated well / average optical density of the 
controls) x 100.  For each drug concentration, the average of the three calculated 
percentages represented the percent of surviving cells for that concentration.  
The half maximal inhibitory concentration was calculated using GraphPad 
Prism (GraphPad Software Incorporated:  La Jolla, CA).   
 
B.  All cell lines were harvested, resuspended in OptiMEM and plated at the 
optimal concentration of cells per well.  After a 24-hour incubation period, drugs 
were added as needed in each well.  On Day 5, a WST-1 colormetric assay was 
performed to determine the cytotoxicity of the drug(s) on the cells.  Calculations 
were performed as previously described under IC50 determination assays.  For 
each concentration, the mean  two standard deviations are reported.  P-values 
were calculated using an unpaired t-test. 
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5.  RESULTS 
Expression of IGF1R in MCF7 (hormone receptor-positive) and triple-
negative breast cancer cell lines.  
Western blots were performed to compare the relative total IGF1R 
expression levels in MCF7, MDA-MB-231, MDA-MB-468, BT-20 and SUM149 
cell lines (Figure 1).  As expected, BT-20 cell lines exhibited the highest levels of 
total IGF1R44.  An intermediate level of expression was noted in MCF7 cells while 
MDA-MB-468 and SUM-149 cells expressed the lowest levels of IGF1R. MDA-
MB-231 total IGF1R expression was not analyzed due to loss of the cell lysate, 
however, other studies have shown that MDA-MB-231 has a similar expression 
to MDA-MB-46840. 
 
AG1024 inhibits the proliferation of hormone receptor-positive and TNBC 
cells in a dose-dependent fashion. 
Dose-response curves were generated to demonstrate the effect of 
AG1024, an IGF1R tyrosine kinase inhibitor, on each cell line.  AG1024 
significantly inhibited the proliferation of the MDA-MB-231 (Fig. 2B), MDA-MB-
468 (Fig. 2C) and SUM149 (Fig. 2E) cell lines in a dose-dependent manner 
(<30% cell viability when incubated with 40M AG1024).  AG1024 also caused 
intermediate growth inhibition in BT20 (Fig. 2D) cells (<40% cell viability when 
incubated with 40M AG1024) and was least effective in MCF7 (Fig. 2A) cells 
(<60% cell viability when incubated with 40M AG1024.) 
 
 16
Figitumumab, when used as a single agent, has no anti-proliferative activity 
in hormone receptor-positive and triple-negative breast cancer cell lines.   
Dose-response curves were generated to demonstrate the effect of 
Figitumumab, an IGF1R targeted antibody, on each cell line (Figure 3).  At 
concentrations ranging from 0M to 0.585M, Figitumumab had no discernible 
inhibitory effect on the proliferation of MCF7, MDA-MB-231, MDA-MB-468, BT20 
and SUM149 cells. 
 
AG1024 enhances the anti-proliferative activity of doxorubicin in MDA-MB-
231, MDA-MB-468 and SUM149 triple-negative breast cancer cell lines. 
AG1024 was combined with doxorubicin to determine if it had an additive 
effect on the anti-proliferative action of paclitaxel. Bar graphs depicting the effect 
of AG1024 alone and in combination with doxorubicin were created for each cell 
line.  Drug combinations were interpreted to cause additive or enhanced 
cytotoxicity if the combination caused a statistically significant decrease in cell 
viability compared to either drug alone.  
The proliferation of MCF7 cells was not inhibited by any of the tested doxorubicin 
concentrations.  When 1M AG1024 was used alone, it was associated with 90% 
cell viability (6%, 95% CI), however when either 0.01M or 0.05M doxorubicin  
was added, the combination led to an 11% decrease in cell viability.  When 1M 




cytotoxicity.  Hence, the observed additive cytoxicity at lower doses is modest 
and not consistent at all dose ranges (Figure 4A).  
In contrast, there was a dramatic decrease in cell viability of MDA-MB-231 
cells when increasing concentrations of doxorubicin were added to 1M AG1024 
(Figure 5A). Doxorubicin alone at 0.01M resulted in 84% cell viability (2%, 95% 
CI) and 1M AG1024 alone led to 67% cell viability (8%, 95% CI).  However, 
adding 0.01M doxorubicin to 1M AG1024 led to 45% cell viability (8%, 
p=0.002) whereas adding 0.05M doxorubicin produced 20% cell viability (2%, 
p=0.001 for 1M AG1024 alone versus combined with 0.05M doxorubicin).  
Combining 0.05M doxorubicin with 1M AG1024 produced the same level of 
inhibition as that achieved by 0.4M doxorubicin used as monotherapy. 
Growth of MDA-MB-468 cells was inhibited by doxorubicin in a dose-
dependent manner.  A decrease in cell viability was appreciated when 0.05M 
doxorubicin was added to 1M AG1024 (Figure 6A).  Incubating MDA-MB-468 
cells with only 0.05M doxorubicin led to approximately 48% cell viability. 
Incubation of cells with 1M AG1024 alone caused 48% cell viability (5%) 
compared to 23% (1%) when 0.05M doxorubicin was added.  It is possible that 
there is an enhanced cytotoxic effect when 1M AG1024 is combined with 
0.01M doxorubicin but this effect may have been obscured by the variation and 
wide standard deviation among the replicates of the 0.01M doxorubicin assay.  
Additive cytotoxic effects were also observed to a lesser degree when comparing 
5M AG1024 alone (40%1%) to 5M AG1024 plus 0.01M doxorubicin  
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(34%4%, p=0.006) and 5M AG1024 plus 0.05M doxorubicin (29%4%, 
p=0.001). 
In BT20 cells, doxorubicin monotherapy caused growth inhibition only at 
the highest concentration tested - 0.4M led to 75% cell viability 15%.  
Enhancement of AG1024’s effect was observed when 1M AG1024 was 
combined with 0.1M doxorubicin  (Figure 7A).  This combination caused 80% 
cell viability (2%) compared to 93% cell viability (5%) when 1M of AG1024 
was used alone or 94% cell viability (6%,) when 0.1M of doxorubicin was used 
alone.  However, a higher concentration of doxorubicin (0.2M) failed to produce 
additive cytotoxicity with 1M AG1024 and inhibited cell viability to a lesser 
extent than 0.1M doxorubicin plus 1M AG1024.  These findings suggest that 
the optimal dose-range for AG1024 and doxorubicin is likely to be achievable in 
vivo.  
 In SUM149 cells, 80% cell viability (3%) was seen when 1M AG1024 
was used alone and 59% cell viability (7%) was noted when 0.2M doxorubicin 
alone was used. Cell viability decreased to 45% (1%) when 0.2M doxorubicin 
was combined with 1M AG1024.  Addition of doxorubicin to 5M and 10M 
AG1024 failed to produce greater inhibition of cell proliferation than 5M or 10M 






AG1024 enhances the anti-proliferative activity of paclitaxel in MDA-MB-
231, MDA-MB-468, BT-20 and SUM149 triple-negative breast cancer cell 
lines. 
AG1024 was combined with paclitaxel to determine if it had an additive 
effect on paclitaxel’s anti-proliferative action. Bar graphs depicting the effect of 
AG1024 alone and in combination with paclitaxel were created for each cell line.  
The proliferation of MCF7 cells was not inhibited by any of the tested paclitaxel 
concentrations and there was no increase in cytotoxicity when paclitaxel and 
AG1024 were combined (Figure 4B).  
Paclitaxel inhibited the growth of all triple negative cell lines in a dose-
dependent manner and enhanced cytotoxicity with combinations of paclitaxel and 
AG1024 was observed in all of the triple-negative cell lines (Figures 5B-8B).  In 
MDA-MB-231 cells, incubation with 1M AG1024 alone led to 67% cell viability 
(8%).  Treatment with 1.136nM and 2.27nM paclitaxel alone resulted in 93% cell 
viability (16%) and 54% cell viability (9%), respectively.  Compared to 1M 
AG1024 alone, adding 1.136nM and 2.27nM paclitaxel resulted in an 18% 
decrease (11%, p=0.008) and 36% decrease in MDA-MB-231 cell viability 
(7%, p=0.0003), respectively. Combining 5M AG1024 with 1.136nM paclitaxel 
failed to produce greater growth inhibition than 5M AG1024 alone in MDA-MB-
231 cells.  However, 49% cell viability (4%) was seen after treatment with 5M 
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AG1024 alone compared to 28% cell viability (8%, p=0.001) after incubation 
with 5M AG1024 and 2.27nM paclitaxel.   
 
In MDA-MB-468 cells, treatment with 1.136nM paclitaxel failed to inhibit 
cell proliferation while using 2.27nM paclitaxel alone caused 69% cell viability 
(10%.)  Incubation with 1M AG1024 alone led to 48% cell viability (5%) and 
adding 2.27nM paclitaxel to 1M AG1024 caused a decrease to 30% cell viability 
(2%).  Also, adding 1.136nM paclitaxel to 5M AG1024 led to a 7% decrease in 
cell viability (40%1% using 5M AG1024 alone compared to 33%1% when 
combined with 1.136nM paclitaxel) and adding 2.27nM led to an 11% decrease 
in cell viability (3%). 
Paclitaxel also inhibited the growth of BT20 cells with increasing doses 
and additive cytotoxicity was observed between the lowest dose of paclitaxel and 
the two highest concentrations of AG1024 (Figure 7B).  Treating BT20 cells with 
1.136nM paclitaxel alone resulted in 79% cell viability (3%).  Treating these 
cells with 5M AG1024 alone caused 57% cell viability (1%) whereas adding 
1.136nM paclitaxel led to 51% cell viability (4%, p=0.03).  Similarly, 10M 
AG1024 alone resulted in 57% cell viability (3%) but with addition of 1.136nM 
paclitaxel, the cell viability fell to 51% (2%, p=0.005). 
In SUM149 cells, enhanced cytotoxicity was evident with multiple 
combinations of paclitaxel and AG1024 (Figure 8B).  Treatment of SUM149 cells 
with 1M AG1024 alone led to 80% cell viability (3%) and incubation with 
1.136nM paclitaxel alone resulted in 69% cell viability (11%); adding 1.136nM 
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paclitaxel to 1M AG1024 further inhibited cell viability to 53% (p=0.04 for 
1.136nM paclitaxel alone versus combined with 1M AG1024).  Treatment of  
 
SUM149 cells with 5M AG1024 alone produced 49% cell viability (4%) and 
adding 1.136nM paclitaxel led to 36% cell viability (1%, p=0.004 for 5M 
AG1024 alone versus combined with 1.136nM paclitaxel). Combinations of 10M 
AG1024 and paclitaxel also provided evidence of increased cytotoxicity when the 
two compounds were combined.  10M AG1024 alone caused 34% cell viability 
(2%) whereas adding 1.136nM paclitaxel led to 28% cell viability.  Using 
concentrations of paclitaxel greater than 1.136nM in combination with any dose 
of AG1024 led to approximately the same level of cellular growth inhibition.  
 
Figitumumab enhances the anti-proliferative activity of doxorubicin in 
MCF7, MDA-MB-468 and SUM149 breast cancer cell lines.  
Figitumumab was combined with doxorubicin to determine if it had an 
additive effect on the anti-proliferative action of doxorubicin.  Bar graphs 
depicting the effect of Figitumumab, a targeted IGF1R antibody, alone and in 
combination with doxorubicin were created for each cell line (Figures 4C-8C).  
Neither doxorubicin nor Figitumumab significantly inhibited the 
proliferation of MCF7 cells as single agents at any of the tested concentrations 
(Figure 4C).  However, increased cytotoxicity was appreciated when 0.175M 
Figitumumab was combined with 0.05M doxorubicin.  Adding 0.05M 
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The proliferation of MDA-MB-231 and MDA-MB-468 cells was inhibited by 
doxorubicin alone (0.05μM-0.4μM); however, Figitumumab alone did not inhibit  
proliferation of these cell lines (Figures 5C and 6C respectively).  Increased 
cytotoxicity was noted when 0.175μM or 0.585μM of Figitumumab was combined 
with 0.05μM of doxorubicin in MDA-MB-468 cells (47%4% and 43%3% cell 
viability, respectively compared to 81%26 cell viability when 0.05 μM of 
doxorubicin was used alone.)  
Doxorubicin and Figitumumab combinations also increased cytotoxicity in 
SUM149 cells.  Treatment with 0.01M doxorubicin alone did not inhibit cellular 
proliferation.  Treatment with 0.1M and 0.2M doxorubicin alone caused 
approximately 100% cell viability, 85% cell viability (7%) and 59% (7%) 
respectively.  When treated with 0.0585μM Figitumumab alone, SUM149 cells 
did not experience inhibition of cell proliferation but adding 0.01μM, 0.1μM and 
0.2μM doxorubicin led to 88% (11%), 54% (4%) and 35% (4%) cell viability, 
respectively (Figure 8C).   Adding doxorubicin to 0.175μM Figitumumab and 
0.585μM Figitumumab led to cell viability levels similar to those seen with 
0.0585μM Figitumumab.  An enhanced cytotoxic effect was not appreciated in 







Figitumumab enhances the anti-proliferative activity of paclitaxel in the 
MCF7 and MDA-MB-231 breast cancer cell lines. 
Figitumumab was combined with paclitaxel to determine if it had an 
additive effect on paclitaxel’s anti-proliferative action. Bar graphs depicting the  
effect of Figitumumab alone and in combination with paclitaxel were created for 
each cell line.  
As single agents, paclitaxel and Figitumumab did not inhibit the 
proliferation of MCF7 cells.  However, increased cytotoxicity was detected at all 
concentrations of Figitumumab when either 2.27nM or 9.09nM paclitaxel was 
added (Figure 4D).  The addition of 2.27nM or 9.09nM paclitaxel to 0.0585μM 
Figitumumab both caused a 30% decrease in cell viability (9%).  When the 
same concentrations of paclitaxel were used in combination with 0.175μM 
Figitumumab, a 23-26% decrease in cell viability was noted.  Combining 
0.585μM Figitumumab with 2.27nM or 9.09nM paclitaxel led to approximately 13-
19% decrease in cell viability.   
Paclitaxel alone significantly inhibited the proliferation of MDA-MB-231 
and MDA-MB-468 cells (2.27nM-18.18nM, Figures 5D and 6D) as well as BT20 
and SUM149 cells (1.136nM-18.18nM, Figures 7D and 8D) whereas 
Figitumumab alone did not inhibit proliferation of these cells.  However, the 
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lowest and intermediate concentrations of Figitumumab (0.0585μM and 
0.175μM) had an increased cytotoxic effect when combined with 2.27nM 
paclitaxel in MDA-MB-231 cells (52%6% and 56%9%, respectively compared 
to 69%1 with 2.27nM paclitaxel alone.)  This effect was not discerned in MDA-













































6.  DISCUSSION 
 
 The primary aim of this study was to explore whether antagonizing the 
IGF1R in triple-negative breast cancer models is a useful therapeutic strategy.  
The association between triple-negative breast cancer, obesity and metabolic 
derangements involving the IGF1R pathway make IGF1R a logical target.  To 
examine the activity of IGF1R antagonists in triple-negative breast cancer cell 
lines, we performed cytoxicity assays using AG1024, an IGF1R tyrosine kinase 
inhibitor, and Figitumumab, an IGF1R specific antibody, as single agents.  As 
triple-negative patients are often treated with doxorubicin or paclitaxel, two 
chemotherapeutic agents, cytoxicity assays testing combinations of these 
reagents with doxorubicin or paclitaxel were also performed.  Although AG1024 
has been studied in triple-negative breast cell lines, there are no studies 
documenting the effect of Figitumumab in these breast cancer cell lines.  
Furthermore, no prior publications have explored if enhanced cytotoxicity is 
achieved when IGF1R inhibitors are combined with doxorubicin or paclitaxel in 
TNBC cell lines. 
 Our results indicate that AG1024 effectively inhibits the proliferation of 
both hormone receptor-positive and TNBC cell lines.  However, in our study, 
AG1024 produced higher levels of inhibition in TNBC cell lines, compared to the 
ER- and PR-positive cell line, MCF7.  After treatment with 40M AG1024, MCF7 
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cells exhibited 52% cell viability whereas treatment of MDA-MB-231 cells, MDA-
MB-468, BT20 and SUM149 cells resulted in 15%, 26%, 34% and 18% cell 
viability, respectively.  Cell lines with the highest level of IGF1R expression  
 
(MCF7 and BT20) were least sensitive to AG1024 whereas the cell lines with 
relatively low levels of IGF1R expression were the most sensitive to AG1024 
(MDA-MB-231, MDA-MB-468 and SUM149.) 
 Evidence of additive cytotoxic effects due to AG1024 and doxorubicin 
combinations was seen in MDA-MB-231, MDA-MB-468 and SUM149 triple-
negative cell lines.  Additive cytotoxicity was evident when the lowest 
concentration of AG1024 (1M) was combined with the lowest concentration of 
doxorubicin (0.01M) in MDA-MB-231 cell lines.  However, this concentration of 
doxorubicin did not increase cytotoxicity when added to 1M AG1024 in MDA-
MB-468 and SUM149 cell lines.  A higher concentration of doxorubicin, 0.05M 
in MDA-MB-468 cell lines and 0.2M in SUM149, was needed to produce 
additive cytotoxic effects.  Also, MDA-MB-468 cells were the only cell line to 
exhibit this effect when 5M AG1024 was combined with doxorubicin. The dose 
of doxorubicin at which additive cytotoxic effects are elicited appears to depend 
on the cell line’s sensitivity to doxorubicin.  The cell lines that were more 
sensitive to doxorubicin (MDA-MB-231 and MDA-MB-468) exhibited increased 
cytotoxicity with AG1024 at a lower concentration of doxorubicin.   
Of note, the cell lines with the highest IGF1R expression levels (MCF7 
and BT20) did not exhibit enhanced cytotoxicity with combinations of AG1024 
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and doxorubicin. In this study, the proliferation of MCF7 cells was not inhibited 
after treatment with concentrations of doxorubicin ranging from 0.01M to 0.4M.   
 
 
Our findings are consistent with other studies that have shown an IC50 as high 
as 5M doxorubicin for MCF7 cells45.  
 Combinations of AG1024 and paclitaxel only produced increased 
cytotoxicity in the TNBC cell lines.  The proliferation of all the TNBC cell lines 
was inhibited by paclitaxel alone.  The cell lines that were most sensitive to 
AG1024 (MDA-MB-231, MDA-MB-468 and SUM149) exhibited increased 
cytotoxicity due to AG1024 and paclitaxel at the lowest concentration of AG1024 
(1M) whereas the cell lines that were less sensitive to AG1024 (BT20) 
demonstrated this effect with a higher dose of AG1024 (5M) but not with the 
lowest dose of AG1024 (1M). Treatment with 1.136nM paclitaxel alone failed to 
inhibit MDA-MB-468 proliferation while cell viability fell to 93% in MDA-MB-231 
cells and approximately 80% in BT20 and SUM149 cells.  Of note, the lowest 
concentration of paclitaxel, 1.136nM, increased cytotoxicity in all cell lines 
regardless of their sensitivity to paclitaxel. In this study, concentrations of 
paclitaxel ranging from 1.136nM to 18.18nM failed to inhibit the cellular 
proliferation of MCF7 cells.  These findings are corroborated by studies that have 
demonstrated an IC50 as high as 200nM for MCF7 cells45.   
Figitumumab, when used as a sole agent, did not inhibit cell proliferation 
regardless of hormone receptor status.  However, there was evidence of 
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increased cytotoxicity due to combinations of Figitumumab and doxorubicin or 
paclitaxel.  At the lowest concentration of Figitumumab that we tested 
(0.0585M), Figitimumab enhanced the cytotoxic effects of both low and high  
 
concentrations of doxorubicin in SUM149 cells.  In MCF7 cells, this effect 
between Figitumumab and doxorubicin was evident at an intermediate dose of 
Figitumumab (0.175M) and an intermediate dose of doxorubicin (0.05M).  A 
similar response was noted in MDA-MB-468 cells which demonstrated increased 
cytotoxicity when intermediate to high doses of Figitumumab (0.175M and 
0.585M) were combined with an intermediate dose of doxorubicin (0.05M.)   
Of note, even though MDA-MB-468 cells were the most sensitive to 
doxorubicin when used as a single agent, an intermediate dose of doxorubicin 
was needed to elicit increased cytotoxicity with Figitumumab.  In contrast, 
SUM149 cells were slightly less sensitive to doxorubicin than MDA-MB-468 cells 
yet they demonstrated this response at low and high doses of doxorubicin.  
Therefore, doxorubicin sensitivity did not predict the concentration at which 
doxorubicin and Figitumumab combinations would enhance cytotoxicity in our 
study. 
Sensitivity to doxorubicin alone also did not predict whether doxorubicin 
and Figitumumab would enhance cytotoxicity.  For instance, MDA-MB-231 cells 
were sensitive to doxorubicin when used as a single agent. Doxorubicin at 
0.01M failed to inhibit the proliferation of MDA-MB-231 cells but 0.05M 
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doxorubicin caused the cell viability to drop sharply to 39%.  However, there was 




combinations in MDA-MB-231 cells whereas MCF7 cells that failed to respond to 
doxorubicin as a single agent, exhibited this effect.   
In MCF7 and MDA-MB-231 cells, Figitumumab enhanced the anti-
proliferative activity of paclitaxel.  In MCF7 cells, this effect was noted at all 
concentrations of Figitumumab and intermediate concentrations of paclitaxel.  In 
MDA-MB-231 cells, increased cytotoxicity was noted when low and intermediate 
concentrations of Figitumumab were combined with a low concentration of 
paclitaxel. Of note, sensitivity to paclitaxel did not predict that increased 
cytotoxicity would occur with Figitumumab and paclitaxel combinations since 
MDA-MB-468, BT20 and SUM149 cells were sensitive to paclitaxel alone but 
failed to experience enhanced cytotoxic effects with Figitumumab and paclitaxel 
combinations. 
This study demonstrates that antagonizing IGF1R is effective in inhibiting 
the proliferation of several triple-negative breast cancer cell lines.  AG1024, a 
receptor tyrosine kinase inhibitor, appeared to be more effective as a single 
agent than Figitumumab, an IGF1R specific antibody.  Moreover, our data show 
that combining AG1024 with paclitaxel enhanced the anti-proliferative activity of 
AG1024 in all the TNBC cell lines . This effect was not as striking in the hormone 
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receptor-positive cell line, MCF7.  Furthermore, combinations of AG1024 and 
doxorubicin caused additive cytotoxicity in three out of four TNBC cell lines. 
The toxicity of doxorubicin and paclitaxel are well-documented. Significant 
adverse reactions associated with doxorubicin include acute or delayed  
 
cardiotoxicity, colon necrosis, gastrointestinal ulceration and infertility.  
Paclitaxel’s side effects include peripheral neuropathy (seen in up to 70% of 
patients), nausea, vomiting, mucositis and increases in creatinine and liver 
enzymes.  Decreasing the amount of doxorubicin or paclitaxel used in 
chemotherapy regimens is a desirable goal since it could reduce the risk of 
adverse reactions and improve the quality of life of patients.   
Although Figitumumab did not inhibit proliferation as a single agent, 
addition of doxorubicin caused additive cytotoxicity in MCF7 cells and one TNBC 
cell lines.  Combining Figitumumab and paclitaxel improved Figitimumab’s ability 
to antagonize cell proliferation in hormone receptor-positive MCF7 cells and two 
TNBC cell lines. 
Our investigation is a preliminary study of IGF1R antagonists alone and in 
combination with chemotherapy in TNBC cell lines. Limitations of this study 
include the small number of cell lines employed.  Testing other TNBC and 
hormone receptor-positive breast cancer cell lines, besides those used in this 
study, is required to further elucidate the effect of AG1024 and Figitumumab on 
these subtypes of breast cancer.  In addition, each cytotoxicity assay was will 
need to be repeated several times in order to ensure that the results we obtained 
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are reproducible.  Furthermore, analysis of IGF1R expression after treatment 
with AG1024 and Figitumumab (alone and in combination with chemotherapy) 
would also provide useful data about the effect of targeted IGF1R therapies.  
Overall, our findings suggest that there is a role for IGF1R antagonism in the 
treatment of TNBC and that kinase inhibitors, like AG1024, may be more 






























Figure 1:  Total IGF1R protein expression in breast carcinoma cell lines.  30g of 
protein from each cell line was loaded on BioRad Ready 4-20% Tris-HCl gel.  Western 
blots were perfomed by Sofya Rodov (SR).  IGF1R, a 95 kiloDalton protein, was 
detected in each of the cell lines.  BT-20 cell lines exhibited the highest levels of total 
IGF1R44.  An intermediate level of expression was noted in MCF7 cells while MDA-MB-
468 and SUM-149 cells expressed the lowest levels of IGF1R. MDA-MB-231 total IGF1R 
expression was not analyzed due to loss of the cell lysate, however, other studies have 
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Figure 2A-E:  Effect of AG1024, a tyrosine kinase inhibitor of IGF1R, on MCF7 (2A), 
a hormone receptor positive breast cancer cell line and triple-negative breast 
cancer cell lines, MDA-MB-231(2B), MDA-MB-468(2C), BT20 (2D) and SUM149 
(2E).  Cells were seeded at their optimal concentration in 96 well plates then 
allowed to adhere overnight.  AG1024 was added the following day (Day 0).  After 5 
days of incubation, the WST-1 assay was performed.  Each point represents the 
percent of surviving cells compared to control (cells not exposed to AG1024).  The 
mean of three wells 2SD (95% CI) is shown.  AG1024 decreased the viability of all 
cell lines in a dose-dependent fashion.  The MCF7 cell line was the least sensitive 
to AG1024.  Assays in Figures 2A-2C were executed by Onyi Offor (OO).  Assays 



















































































































Figure 3A-E:  Effect of Figitumumab, an IGF1R targeted antibody, on MCF7 (3A), a 
hormone receptor positive breast cancer cell line and triple-negative breast cancer 
cell lines, MDA-MB-231 (3B), MDA-MB-468(3C), BT20 (3D) and SUM149 (3E).  
Cells were seeded at their optimal concentration in 96 well plates then allowed to 
adhere overnight.  Figitumumab was added the following day (Day 0).  After 5 days 
of incubation, the WST-1 assay was performed.  Each point represents the percent 
of surviving cells compared to control (cells not exposed to Figitumumab.)  The 
mean of three wells 2SD (95% CI) is shown.  Figitumumab monotherapy failed to 
have a cytotoxic effect in all of the cell lines.  Assay in Figure 3A, 3D and 3E was 
executed by SR.  Assays in Figures 3B and 3C were executed by OO. 
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Figure 4:  Effect of AG1024, an IGF1R tyrosine kinase inhibitor, and Figitumumab, an 
IGF1R targeted antibody, alone and in combination with conventional chemotherapeutic 
agents, doxorubicin and paclitaxel, in MCF7 cells.  Cells were plated at 1000 cells/well 
and allowed to adhere overnight.  Drugs were applied the next day (Day 0).  WST-1 
assay was performed on Day 5.  Each bar represents the average of three wells  2SD 
(95% CI).  Doxorubicin or paclitaxel concentrations increase along the x-axis.  Each 
color represents a different concentration of AG1024 or Figitumumab tested (blue bars = 
0M AG1024 in Figs. 4A and 4B or 0M Figitumumab in Figs. 4C and 4D, maroon bars 
= 0.01M doxorubicin in Figures 4A and 4B or 0.0585M Figitumumab in Figures 4C 
and 4D and so forth).  Increased cytotoxicity was seen with combinations of 
Figitumumab and AG1024 (Fig. 4C) and Figitumumab and paclitaxel (Fig. 4D.)  
Fig. 4C:  Adding 0.05M doxorubicin to 0.175M Figitumumab caused cell 
viability to decrease by 11% (6%, p=0.005) compared to using 0.175M Figitumumab 
alone.  
Fig. 4D:  Increased cytotoxicity was detected at all concentrations of 
Figitumumab when either 2.27nM or 9.09nM paclitaxel was added (Figure 4D).  The 
addition of 2.27nM or 9.09nM paclitaxel to 0.0585μM Figitumumab both caused a 30% 
decrease in cell viability (9%).  When the same concentrations of paclitaxel were used 
in combination with 0.175μM Figitumumab, a 23-26% decrease in cell viability was 
noted.  Combining 0.585μM Figitumumab with 2.27nM or 9.09nM paclitaxel led to 
approximately 13-19% decrease in cell viability.  Assays in Figures 4A and 4D were 
executed by OO and SR respectively.  Assays in Figures 4B and 4C were executed 
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Figure 5:  Effect of AG1024, an IGF1R tyrosine kinase inhibitor, and Figitumumab, an 
IGF1R targeted antibody, alone and in combination with conventional chemotherapeutic 
agents, doxorubicin and paclitaxel, in MDA-MB-231 cells.  Cells were plated at 1500 
cells/well and allowed to adhere overnight.  Drugs were applied the next day (Day 0).  
WST-1 assay was performed on Day 5.  Each bar represents the average of three wells 
 2SD (95% CI). Each color represents a different concentration of AG1024 or 
Figitumumab tested (blue bars = 0M AG1024 in Figs. 5A and 5B or 0M Figitumumab 
in Figs. 5C and 5D, maroon bars = 0.01M doxorubicin in Figures 5A and 5B or 
0.0585M Figitumumab in Figures 5C and 5D and so forth). Figitumumab monotherapy 
failed to cause a decrease in cell viability.  Combining AG1024 and doxorubicin (Figure 
5A), AG1024 and paclitaxel (Fig. 5B) as well as Figitumumab and paclitaxel (Fig. 5D) 
showed an increased cytotoxic effect compared to these agents alone.  
Fig. 5A:  Doxorubicin alone at 0.01M resulted in 84% cell viability (2%, 95% 
CI) and 1M AG1024 alone led to 67% cell viability (8%, 95% CI).  However, adding 
0.01M doxorubicin to 1M AG1024 led to 45% cell viability (8%, p=0.002) whereas 
adding 0.05M doxorubicin produced 20% cell viability (2%, p=0.001 for 1M AG1024 
alone versus combined with 0.05M doxorubicin).   
Fig. 5B:  Compared to 1M AG1024 alone, adding 1.136nM and 2.27nM 
paclitaxel resulted in an 18% decrease (11%, p=0.008) and 36% decrease in MDA-MB-
231 cell viability (7%, p=0.0003), respectively. Combining 5M AG1024 with 1.136nM 
paclitaxel failed to produce greater growth inhibition than 5M AG1024 alone in MDA-
MB-231 cells.  However, 49% cell viability (4%) was seen after treatment with 5M 
AG1024 alone compared to 28% cell viability (8%, p=0.001) after incubation with 5M 
AG1024 and 2.27nM paclitaxel.   
Fig. 5D:  The addition of 2.27nM or 9.09nM paclitaxel to 0.0585μM Figitumumab 
both caused a 30% decrease in cell viability (9%).  When the same concentrations of 
paclitaxel were used in combination with 0.175μM Figitumumab, a 23-26% decrease in 
cell viability was noted.  Combining 0.585μM Figitumumab with 2.27nM or 9.09nM 
paclitaxel led to approximately 13-19% decrease in cell viability.  Assays in Figures 5C 
and 5D were executed by OO and SR respectively.  Assays in Figures 5A and 5B were 
executed jointly with SR and OO 
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Figure 6:  Effect of AG1024, an IGF1R tyrosine kinase inhibitor, and Figitumumab, an 
IGF1R targeted antibody, alone and in combination with conventional chemotherapeutic 
agents, doxorubicin and paclitaxel, in MDA-MB-468 cells.  Cells were plated at 3000 
cells/well and allowed to adhere overnight.  Drugs were applied the next day (Day 0).  
WST-1 assay was performed on Day 5.  Each bar represents the average of three wells 
 2SD (95% CI). Each color represents a different concentration of AG1024 or 
Figitumumab tested (blue bars = 0M AG1024 in Figs. 6A and 6B or 0M Figitumumab 
in Figs. 6C and 6D, maroon bars = 0.01M doxorubicin in Figures 6A and 6B or 
0.0585M Figitumumab in Figures 6C and 6D and so forth). Combining AG1024 and 
doxorubicin (Figure 6A) and Figitumumab and doxorubicin (Fig. 6C) showed an 
increased cytotoxic effect compared to these agents alone.  
Fig. 6A:  Treating MDA-MB-468 cells with only 0.05M doxorubicin or only 1M 
AG1024 led to approximately 48% cell viability compared to 23% (1%) when 1M 
AG1024 and 0.05M doxorubicin were combined (Fig. 6A).  Additive cytotoxic effects 
were also observed to a lesser degree when comparing 5M AG1024 alone (40%1%) 
to 5M AG1024 plus 0.01M doxorubicin (34%4%, p=0.006) and 5M AG1024 plus 
0.05M doxorubicin (29%4%, p=0.001).  
Fig. 6C:  Increased cytotoxicity was noted when 0.175μM or 0.585μM of 
Figitumumab was combined with 0.05μM of doxorubicin in MDA-MB-468 cells (47%4% 
and 43%3% cell viability, respectively compared to 81%26 cell viability when 0.05 μM 
of doxorubicin was used alone.) Assays in Figures 6A, 6C and 6D were executed by 
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Figure 7:  Effect of AG1024, an IGF1R tyrosine kinase inhibitor, and Figitumumab, an 
IGF1R targeted antibody, alone and in combination with conventional chemotherapeutic 
agents, doxorubicin and paclitaxel, in BT20 cells.  Cells were plated at 1000 cells/well 
and allowed to adhere overnight.  Drugs were applied the next day (Day 0).  WST-1 
assay was performed on Day 5.  Each bar represents the average of three wells  2SD 
(95% CI). Color-coding of the bars is similar to that described in Figs. 4-6. Combining 
AG1024 and paclitaxel (Fig. 7B) showed an increased cytotoxic effect compared to 
these agents alone. Treating BT20 cells with 1.136nM paclitaxel alone resulted in 79% 
cell viability (3%).  Treating these cells with 5M AG1024 alone caused 57% cell 
viability (1%) whereas adding 1.136nM paclitaxel led to 51% cell viability (4%, 
p=0.03).  Similarly, 10M AG1024 alone resulted in 57% cell viability (3%) but with 
addition of 1.136nM paclitaxel, the cell viability fell to 51% (2%, p=0.005).  Assays in 
Figures 7A and 7D were executed by OO and SR respectively.  Assays in Figures 7B 
and 7C were executed jointly by OO and SR. 
 
 


























































Figure 8:  Effect of AG1024, an IGF1R tyrosine kinase inhibitor, and Figitumumab, an 
IGF1R targeted antibody, alone and in combination with conventional chemotherapeutic 
agents, doxorubicin and paclitaxel, in SUM149 cells.  Cells were plated at 3000 cells/well 
and allowed to adhere overnight.  Drugs were applied the next day (Day 0).  WST-1 
assay was performed on Day 5.  Each bar represents the average of three wells  2SD 
(95% CI). Color-coding of the bars is similar to that described in Figs. 4-6.  Combining 
AG1024 and doxorubicin (Figure 8A), AG1024 and paclitaxel (Fig. 8B) and Figitumumab 
and doxorubicin (Fig. 8C) showed an increased cytotoxic effect compared to these 
agents alone.  
Fig. 8A: Cell viability decreased to 45% (1%) when 0.2M doxorubicin was 
combined with 1M AG1024 compared to 80% cell viability (3%) when 1M AG1024 
was used alone or 59% cell viability (7%) 0.2M doxorubicin monotherapy was used.  
Fig. 8B:  Combining 1.136nM paclitaxel with any concentration of AG1024 led to 
enhanced cytotoxic effects compared to either reagent alone.  Treatment of SUM149 
cells with 1M AG1024 alone led to 80% cell viability (3%) and incubation with 1.136nM  
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paclitaxel alone resulted in 69% cell viability (11%); adding 1.136nM paclitaxel to 1M 
AG1024 further inhibited cell viability to 53% (p=0.04 for 1.136nM paclitaxel alone versus 
combined with 1M AG1024).  Treatment of SUM149 cells with 5M AG1024 alone 
produced 49% cell viability (4%) and adding 1.136nM paclitaxel led to 36% cell viability 
(1%, p=0.004 for 5M AG1024 alone versus combined with 1.136nM paclitaxel). 
Treatment using 10M AG1024 alone caused 34% cell viability (2%) whereas adding 
1.136nM paclitaxel led to 28% cell viability. Treatment with 0.01M or 0.05M 
doxorubicin alone did not inhibit cellular proliferation but treatment with 0.1M and 
0.2M doxorubicin alone caused approximately 85% cell viability (7%) and 59% (7%) 
respectively.   
Fig. 8C:  When treated with 0.0585μM Figitumumab alone, SUM149 cells did not 
experience inhibition of cell proliferation but adding 0.01μM, 0.1μM and 0.2μM 
doxorubicin led to 88% (11%), 54% (4%) and 35% (4%) cell viability, respectively 
(Figure 8C).  Assays in Figures 8A and 8D were executed by OO and SR respectively.  
Assays in Figures 8B and 8C were executed jointly by OO and SR. Doxorubicin and 
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